vs
Side-by-side financial comparison of Becton Dickinson (BDX) and Ferguson Enterprises Inc. (FERG). Click either name above to swap in a different company.
Ferguson Enterprises Inc. is the larger business by last-quarter revenue ($8.2B vs $5.3B, roughly 1.6× Becton Dickinson). Becton Dickinson runs the higher net margin — 7.3% vs 7.0%, a 0.3% gap on every dollar of revenue. On growth, Ferguson Enterprises Inc. posted the faster year-over-year revenue change (5.1% vs -0.4%). Becton Dickinson produced more free cash flow last quarter ($549.0M vs $312.0M). Over the past eight quarters, Ferguson Enterprises Inc.'s revenue compounded faster (10.6% CAGR vs 2.0%).
Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.
Ferguson Enterprises Inc., headquartered in Newport News, Virginia and organized in Delaware, is the largest U.S. distributor of plumbing, heating, ventilation and air conditioning (HVAC), appliances, and lighting to pipes, valves and fittings (PVF), and water and wastewater products. The company receives 95% of its revenue in the United States and 5% of its revenue in Canada. The company has 36,000 suppliers and operates from 11 regional distribution centers, four MDCs, approximately 5,900 f...
BDX vs FERG — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.3B | $8.2B |
| Net Profit | $382.0M | $570.0M |
| Gross Margin | 45.9% | 30.7% |
| Operating Margin | 10.5% | 9.4% |
| Net Margin | 7.3% | 7.0% |
| Revenue YoY | -0.4% | 5.1% |
| Net Profit YoY | 24.0% | 21.3% |
| EPS (diluted) | $1.34 | $2.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.3B | $8.2B | ||
| Q3 25 | $5.9B | $8.5B | ||
| Q2 25 | $5.5B | $7.6B | ||
| Q1 25 | $5.3B | $6.9B | ||
| Q4 24 | $5.2B | $7.8B | ||
| Q3 24 | $5.4B | $7.9B | ||
| Q2 24 | $5.0B | $7.3B | ||
| Q1 24 | $5.0B | $6.7B |
| Q4 25 | $382.0M | $570.0M | ||
| Q3 25 | $493.0M | $700.0M | ||
| Q2 25 | $574.0M | $410.0M | ||
| Q1 25 | $308.0M | $276.0M | ||
| Q4 24 | $303.0M | $470.0M | ||
| Q3 24 | $400.0M | $451.0M | ||
| Q2 24 | $487.0M | $443.0M | ||
| Q1 24 | $537.0M | $322.0M |
| Q4 25 | 45.9% | 30.7% | ||
| Q3 25 | 47.5% | 31.7% | ||
| Q2 25 | 47.8% | 31.0% | ||
| Q1 25 | 42.8% | 29.7% | ||
| Q4 24 | 43.2% | 30.1% | ||
| Q3 24 | 45.7% | 31.0% | ||
| Q2 24 | 46.2% | 30.5% | ||
| Q1 24 | 45.7% | 30.4% |
| Q4 25 | 10.5% | 9.4% | ||
| Q3 25 | 11.8% | 10.9% | ||
| Q2 25 | 16.0% | 8.0% | ||
| Q1 25 | 10.4% | 6.0% | ||
| Q4 24 | 8.8% | 8.6% | ||
| Q3 24 | 11.4% | 10.2% | ||
| Q2 24 | 12.1% | 8.6% | ||
| Q1 24 | 14.5% | 7.1% |
| Q4 25 | 7.3% | 7.0% | ||
| Q3 25 | 8.4% | 8.2% | ||
| Q2 25 | 10.4% | 5.4% | ||
| Q1 25 | 5.8% | 4.0% | ||
| Q4 24 | 5.9% | 6.0% | ||
| Q3 24 | 7.4% | 5.7% | ||
| Q2 24 | 9.8% | 6.1% | ||
| Q1 24 | 10.6% | 4.8% |
| Q4 25 | $1.34 | $2.90 | ||
| Q3 25 | $1.71 | $3.53 | ||
| Q2 25 | $2.00 | $2.07 | ||
| Q1 25 | $1.07 | $1.38 | ||
| Q4 24 | $1.04 | $2.34 | ||
| Q3 24 | $1.37 | $2.23 | ||
| Q2 24 | $1.68 | $2.18 | ||
| Q1 24 | $1.85 | $1.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $740.0M | $526.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $25.3B | $6.1B |
| Total Assets | $54.8B | $17.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $740.0M | $526.0M | ||
| Q3 25 | $641.0M | $674.0M | ||
| Q2 25 | $735.0M | $519.0M | ||
| Q1 25 | $667.0M | $764.0M | ||
| Q4 24 | $711.0M | $601.0M | ||
| Q3 24 | $1.7B | $571.0M | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $2.3B | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $4.2B | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $4.0B | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $25.3B | $6.1B | ||
| Q3 25 | $25.4B | $5.8B | ||
| Q2 25 | $25.5B | $5.5B | ||
| Q1 25 | $25.2B | $5.5B | ||
| Q4 24 | $25.2B | $5.7B | ||
| Q3 24 | $25.9B | $5.6B | ||
| Q2 24 | $25.9B | $5.5B | ||
| Q1 24 | $25.6B | $5.4B |
| Q4 25 | $54.8B | $17.7B | ||
| Q3 25 | $55.3B | $17.7B | ||
| Q2 25 | $54.9B | $17.3B | ||
| Q1 25 | $54.5B | $16.5B | ||
| Q4 24 | $54.7B | $16.9B | ||
| Q3 24 | $57.3B | $16.6B | ||
| Q2 24 | $55.6B | — | ||
| Q1 24 | $54.2B | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $657.0M | $430.0M |
| Free Cash FlowOCF − Capex | $549.0M | $312.0M |
| FCF MarginFCF / Revenue | 10.5% | 3.8% |
| Capex IntensityCapex / Revenue | 2.1% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.72× | 0.75× |
| TTM Free Cash FlowTrailing 4 quarters | $2.6B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $657.0M | $430.0M | ||
| Q3 25 | $1.4B | $541.0M | ||
| Q2 25 | $1.2B | $682.0M | ||
| Q1 25 | $164.0M | $340.0M | ||
| Q4 24 | $693.0M | $345.0M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $514.0M | — |
| Q4 25 | $549.0M | $312.0M | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | $605.0M | ||
| Q1 25 | $35.0M | $259.0M | ||
| Q4 24 | $588.0M | $268.0M | ||
| Q3 24 | $882.0M | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $380.0M | — |
| Q4 25 | 10.5% | 3.8% | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 19.0% | 7.9% | ||
| Q1 25 | 0.7% | 3.8% | ||
| Q4 24 | 11.4% | 3.4% | ||
| Q3 24 | 16.2% | — | ||
| Q2 24 | 22.4% | — | ||
| Q1 24 | 7.5% | — |
| Q4 25 | 2.1% | 1.4% | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 3.2% | 1.0% | ||
| Q1 25 | 2.4% | 1.2% | ||
| Q4 24 | 2.0% | 1.0% | ||
| Q3 24 | 5.4% | — | ||
| Q2 24 | 3.6% | — | ||
| Q1 24 | 2.7% | — |
| Q4 25 | 1.72× | 0.75× | ||
| Q3 25 | 2.75× | 0.77× | ||
| Q2 25 | 2.12× | 1.66× | ||
| Q1 25 | 0.53× | 1.23× | ||
| Q4 24 | 2.29× | 0.73× | ||
| Q3 24 | 2.94× | — | ||
| Q2 24 | 2.66× | — | ||
| Q1 24 | 0.96× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
FERG
| United States Segment | $7.8B | 95% |
| Other | $412.0M | 5% |
